Impact of age and frailty on the effect of a multimodal individualized long-term intervention after stroke: the last-long trial.

J Rehabil MedOct 26, 2026 (epub)

Håkon Ihle-Hansen, Bente Thommessen, Sara Rise Langlo et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-blinded, multicentre randomized controlled trial examined whether age or frailty modified response to a stroke coordinator-led, individualized community intervention. At four Norwegian hospitals, 301 participants were assigned to monthly meetings for 18 months or standard care; the primary outcome was modified Rankin Scale (mRS) at 18 months. Age modified the intervention effect: among participants aged ≥ 80 years, favourable mRS outcome was less likely with intervention than control (23.4% vs 57.0%, p = 0.004). Frailty did not modify the intervention effect. The trial had found no overall functional benefit.

Key findings

  • Among participants aged ≥ 80 years, favourable mRS outcome occurred in 23.4% with intervention versus 57.0% with control (p = 0.004).
  • In younger participants, intervention improved Trail Making Test B by -32.2 s (95% CI -58.0 to -6.4, p = 0.015); the age-intervention interaction was significant (p = 0.019).
  • No interaction between frailty and intervention was found.

Why it matters

The findings suggest that age may be relevant when evaluating responses to prolonged, individualized post-stroke support: the intervention’s effects were not uniform across age groups, and the oldest participants had less favourable mRS outcomes with intervention than with standard care. The cognitive result in younger participants also indicates that effects may differ by outcome. These subgroup findings warrant cautious interpretation alongside the absence of overall functional benefit.

What to keep in mind

The age- and frailty-related findings are subgroup analyses of a trial that found no overall functional benefit; mRS data were available for 268 of 301 randomized participants.

Source

Published in J Rehabil Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.